Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis

OBJECTIVE We have developed a new antihyperglycemic agent (teglicar) through the selective and reversible inhibition of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). RESEARCH DESIGN AND METHODS Glucose production was investigated in isolated hepatocytes and during pancreatic clamps in healthy rats. Chronic treatments on C57BL/6J, db/db, high-fat fed mice, and rats were performed to understand glucose metabolism and insulin sensitivity. RESULTS In isolated hepatocytes, teglicar concentration dependently reduced ketone bodies and glucose production up to 72 and 50%, respectively. In rats, teglicar reduced the endogenous glucose production (−62%) without affecting peripheral glucose utilization. Heart 2-[3H]deoxyglucose uptake in mice was also not affected, confirming in vivo the drug selectivity toward L-CPT1. Chronic treatment in db/db mice (50 mg/kg/bid; 45 days) reduced postabsorptive glycemia (−38%), water consumption (−31%), and fructosamine (−30%). Such antidiabetic activity was associated with an improved insulin sensitivity assessed by the insulin tolerance test. A significant 50% increase in hepatic triglyceride content (HTGC) was found, although plasma alanineaminotransferase was not altered. In addition, long-term teglicar administration to high-fat fed C57BL/6J mice normalized glycemia (−19%) and insulinemia (−53%). Long-term teglicar administration (30 days, 80 mg/kg) in healthy overnight-fasted rats slightly reduced basal glycemia (−20%, ns), reduced basal insulin levels by 60%, doubled triglycerides, and increased free-fatty acids (+53%). HTGC was markedly increased, but liver and peripheral insulin sensitivity assessed by hyperinsulinemiceuglycemic clamp were not affected. CONCLUSIONS Teglicar, in vitro and in animal models, reduces gluconeogenesis and improves glucose homeostasis, refreshing the interest in selective and reversible L-CPT1 inhibition as a potential antihyperglycemic approach.

[1]  C. Townsend,et al.  Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. , 2000, Science.

[2]  J. Girard,et al.  Molecular and enzymatic characterization of a unique carnitine palmitoyltransferase 1A mutation in the Hutterite community. , 2001, Molecular genetics and metabolism.

[3]  J. McGarry,et al.  The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. , 1997, European journal of biochemistry.

[4]  P. J. Randle,et al.  Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. , 1998, Diabetes/metabolism reviews.

[5]  P. Fasching,et al.  Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. , 1991, Metabolism: clinical and experimental.

[6]  L. Mandarino,et al.  Mechanism of hyperglycemia and response to treatment with an inhibitor of fatty acid oxidation in a patient with insulin resistance due to antiinsulin receptor antibodies. , 1984, The Journal of clinical endocrinology and metabolism.

[7]  M. Mozzoli,et al.  Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. , 2001, Diabetes.

[8]  D. James,et al.  Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. , 1985, The American journal of physiology.

[9]  B. Viollet,et al.  Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.

[10]  R. Hanson,et al.  Gluconeogenesis, its regulation in mammalian species , 1976 .

[11]  R. Rizza,et al.  Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.

[12]  M. Rigoulet,et al.  Stimulation by glucose of gluconeogenesis in hepatocytes isolated from starved rats. , 1987, The Biochemical journal.

[13]  P. Lazarow.  Assay of peroxisomal beta-oxidation of fatty acids. , 1981, Methods in enzymology.

[14]  B. Teusink,et al.  Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. , 2005, Journal of lipid research.

[15]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[16]  J. Schölmerich,et al.  Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis. , 2004, American journal of physiology. Endocrinology and metabolism.

[17]  H. Reinauer,et al.  Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure and substrate oxidation in NIDDM. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  J. Stoler,et al.  Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation , 2004, Journal of Inherited Metabolic Disease.

[19]  J. Romijn,et al.  Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[20]  M. Lane,et al.  Hypothalamic malonyl-CoA as a mediator of feeding behavior , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Häkkinen,et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.

[22]  M. Bennett,et al.  Novel mutations in CPT 1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. , 2004, Molecular genetics and metabolism.

[23]  T P Stein,et al.  Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. , 2001, American journal of physiology. Endocrinology and metabolism.

[24]  Roberto Conti,et al.  Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production , 2003, Nature Medicine.

[25]  Gary W. Cline,et al.  Glycerol-3-Phosphate Acyltransferase 1 Deficiency in ob/ob Mice Diminishes Hepatic Steatosis but Does Not Protect Against Insulin Resistance or Obesity , 2010, Diabetes.

[26]  A. Arduini,et al.  Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity. , 2003, Journal of medicinal chemistry.

[27]  R. DeFronzo,et al.  Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[28]  R. Kulkarni,et al.  A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. , 2000, Diabetes.

[29]  R. DeFronzo,et al.  Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.

[30]  S. Schmidt-Schweda,et al.  First clinical trial with etomoxir in patients with chronic congestive heart failure. , 2000, Clinical science.

[31]  B. Ljung,et al.  Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. , 2001, Diabetes.

[32]  J. Foley,et al.  Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors. , 1995, Journal of medicinal chemistry.

[33]  J. Foley,et al.  Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  J. McGarry,et al.  Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. , 2001, Diabetes.

[35]  M. Berry,et al.  Isolated Hepatocytes: Preparation, Properties and Applications , 1991 .

[36]  R. Coccurello,et al.  Effects of the increase in neuronal fatty acids availability on food intake and satiety in mice , 2010, Psychopharmacology.

[37]  J. Mccormack,et al.  Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. , 2001, Current pharmaceutical design.

[38]  J. Proietto,et al.  Molecular Mechanisms of Increased Glucose Production: Identifying Potential Therapeutic Targets , 2004, Journal of Investigative Medicine.

[39]  L. Rossetti,et al.  Minireview: nutrient sensing and the regulation of insulin action and energy balance. , 2003, Endocrinology.

[40]  S. Litwin,et al.  Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. , 1990, The American journal of physiology.

[41]  R. Anderson.  Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM? , 1970, Current pharmaceutical design.

[42]  J. Romijn,et al.  Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400440-JLR200 , 2005, Journal of Lipid Research.

[43]  J C Stanley,et al.  The glucose-fatty acid cycle. Relationship between glucose utilization in muscle, fatty acid oxidation in muscle and lipolysis in adipose tissue. , 1981, British journal of anaesthesia.